DE1900307A1 - Neues Kombinationspraeparat und seine Herstellung - Google Patents
Neues Kombinationspraeparat und seine HerstellungInfo
- Publication number
- DE1900307A1 DE1900307A1 DE19691900307 DE1900307A DE1900307A1 DE 1900307 A1 DE1900307 A1 DE 1900307A1 DE 19691900307 DE19691900307 DE 19691900307 DE 1900307 A DE1900307 A DE 1900307A DE 1900307 A1 DE1900307 A1 DE 1900307A1
- Authority
- DE
- Germany
- Prior art keywords
- combination preparation
- preparation according
- methyl
- caffeine
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 30
- 238000004519 manufacturing process Methods 0.000 title description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 52
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 27
- 229960001948 caffeine Drugs 0.000 claims description 27
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 27
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims description 24
- NZLVRVYNQYGMAB-UHFFFAOYSA-N 1-methyl-4-(9-thioxanthenylidene)piperidine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2SC2=CC=CC=C21 NZLVRVYNQYGMAB-UHFFFAOYSA-N 0.000 claims description 21
- BOLCFGMGGWCOOE-UHFFFAOYSA-N Ergostine Natural products N12C(=O)C(CC)(NC(=O)C3C=C4C=5C=CC=C6NC=C(C=56)CC4N(C)C3)OC2(O)C2CCCN2C(=O)C1CC1=CC=CC=C1 BOLCFGMGGWCOOE-UHFFFAOYSA-N 0.000 claims description 15
- 229960004943 ergotamine Drugs 0.000 claims description 9
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 9
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 9
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical class C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- 229960003133 ergot alkaloid Drugs 0.000 claims description 6
- 229940095064 tartrate Drugs 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 5
- DFWHWFLWRXBPGX-UHFAATNVSA-N ac1l4w55 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)CC)C1=CC=CC=C1 DFWHWFLWRXBPGX-UHFAATNVSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960004704 dihydroergotamine Drugs 0.000 claims description 4
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 4
- BGHDUTQZGWOQIA-RKUMIMICSA-N ergovaline Natural products O=C(N[C@@]1(C)C(=O)N2[C@H](C(C)C)C(=O)N3[C@@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23 BGHDUTQZGWOQIA-RKUMIMICSA-N 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- BOLCFGMGGWCOOE-CTTKVJGISA-N ergostine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@@H]1C=C2C=3C=CC=C4NC=C(C=34)C[C@H]2N(C)C1)CC)C1=CC=CC=C1 BOLCFGMGGWCOOE-CTTKVJGISA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- 239000003701 inert diluent Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 229960000399 pimethixene Drugs 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 239000000829 suppository Substances 0.000 description 11
- 239000000049 pigment Substances 0.000 description 9
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 8
- 229960001903 ergotamine tartrate Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008101 lactose Substances 0.000 description 7
- 229940116364 hard fat Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229920002545 silicone oil Polymers 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 3
- 229960003988 indigo carmine Drugs 0.000 description 3
- 235000012738 indigotine Nutrition 0.000 description 3
- 239000004179 indigotine Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- BGHDUTQZGWOQIA-VQSKNWBGSA-N Ergovaline Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)C(C)C)C)C2)=C3C2=CNC3=C1 BGHDUTQZGWOQIA-VQSKNWBGSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229940085891 caffeine 100 mg Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- -1 Polyethylene Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940076092 ergotamine tartrate 1 mg Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH35068 | 1968-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1900307A1 true DE1900307A1 (de) | 1969-09-04 |
Family
ID=4185009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691900307 Pending DE1900307A1 (de) | 1968-01-09 | 1969-01-03 | Neues Kombinationspraeparat und seine Herstellung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3557287A (OSRAM) |
| AT (1) | AT305491B (OSRAM) |
| BE (1) | BE726570A (OSRAM) |
| BR (1) | BR6905370D0 (OSRAM) |
| CA (1) | CA921402A (OSRAM) |
| DE (1) | DE1900307A1 (OSRAM) |
| FR (1) | FR8187M (OSRAM) |
| GB (1) | GB1247801A (OSRAM) |
| IE (1) | IE32612B1 (OSRAM) |
| IL (1) | IL31384A (OSRAM) |
| NL (1) | NL6818027A (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4165376A (en) * | 1971-01-29 | 1979-08-21 | Lake Shore Roentgenology, Ltd. | Treatment of the acute after-effects resulting from alcohol ingestion |
| US5069911A (en) * | 1985-02-05 | 1991-12-03 | Sandoz Ltd. | Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions |
| EP1306376A1 (en) * | 2001-10-25 | 2003-05-02 | Biofrontera Pharmaceuticals AG | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| US7060711B2 (en) * | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| NZ572901A (en) | 2003-06-27 | 2010-06-25 | Janssen Pharmaceutica Nv | Tricyclic delta opioid modulators |
| US7553850B2 (en) * | 2004-08-05 | 2009-06-30 | Janssen Pharmaceutica Nv | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators |
| EP1655027A1 (en) * | 2004-11-04 | 2006-05-10 | Biofrontera Pharmaceuticals GmbH | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine |
| WO2006069277A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | TRICYCLIC δ-OPIOID MODULATORS |
| CA2592462A1 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| EP1833826B1 (en) | 2004-12-22 | 2009-05-27 | Janssen Pharmaceutica N.V. | Tricyclic delta-opioid modulators |
| KR20070104380A (ko) * | 2005-01-06 | 2007-10-25 | 얀센 파마슈티카 엔.브이. | 트리사이클릭 δ-오피오이드 조절제 |
| RU2008101667A (ru) * | 2005-06-16 | 2009-07-27 | Янссен Фармацевтика Н.В. (Be) | Трициклические модуляторы опиоидов |
| WO2014117863A1 (en) | 2013-02-01 | 2014-08-07 | Biofrontera Bioscience Gmbh | Salt polymorph of thioxanthene - 9 - ylidene - 1 - methyl piperidine acid addition salts as antimigraine compounds |
-
1968
- 1968-12-16 NL NL6818027A patent/NL6818027A/xx unknown
- 1968-12-23 FR FR179962A patent/FR8187M/fr not_active Expired
- 1968-12-31 US US788351A patent/US3557287A/en not_active Expired - Lifetime
-
1969
- 1969-01-03 DE DE19691900307 patent/DE1900307A1/de active Pending
- 1969-01-07 IE IE27/69A patent/IE32612B1/xx unknown
- 1969-01-07 CA CA039427A patent/CA921402A/en not_active Expired
- 1969-01-07 AT AT9769A patent/AT305491B/de not_active IP Right Cessation
- 1969-01-07 BR BR205370/69A patent/BR6905370D0/pt unknown
- 1969-01-07 BE BE726570D patent/BE726570A/xx unknown
- 1969-01-08 IL IL31384A patent/IL31384A/en unknown
- 1969-01-08 GB GB0220/69A patent/GB1247801A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT305491B (de) | 1973-02-26 |
| GB1247801A (en) | 1971-09-29 |
| IE32612L (en) | 1969-07-09 |
| IE32612B1 (en) | 1973-10-03 |
| BR6905370D0 (pt) | 1973-02-08 |
| BE726570A (OSRAM) | 1969-07-07 |
| US3557287A (en) | 1971-01-19 |
| IL31384A (en) | 1972-10-29 |
| IL31384A0 (en) | 1969-03-27 |
| FR8187M (OSRAM) | 1970-09-07 |
| CA921402A (en) | 1973-02-20 |
| NL6818027A (OSRAM) | 1969-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3688296T2 (de) | Arzneimittel zur behandlung von erbrechen. | |
| DE69610323T2 (de) | Sich schnell im munde auflösende zusammensetzungen für dopaminagonisten | |
| DE69534975T2 (de) | Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern | |
| DE3915347C2 (de) | Harzadsorbate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE69732113T2 (de) | Schnelllösliche tablette enthaltend galanthaminhydrobromid | |
| DE3318649A1 (de) | Zweiphasenformulierung | |
| DE3855323T2 (de) | Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung | |
| KR20020081271A (ko) | 물질 남용의 치료 방법 | |
| DE69209140T2 (de) | Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen | |
| DE60013466T2 (de) | Im mund zerfallende zusammensetzung mit mirtazapin | |
| EP0205865B1 (de) | Pharmazeutische Präparate mit antihypertensiver und kardioprotektiver Wirkung | |
| DE2937489A1 (de) | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase | |
| DE1911467A1 (de) | Mittel zum Senken des Cholesterinspiegels | |
| Duchemin et al. | Pharmacological characterization of 3H-LSD binding sites in mouse brain in vivo | |
| EP1161241B1 (de) | Stabile pharmazeutische anwendungsform für paroxetin-anhydrat | |
| DE1792271C3 (de) | Blutdrucksenkendes Arzneimittel | |
| DE3887426T2 (de) | Eperisone als Hypotonikum. | |
| DE3904795A1 (de) | Pharmazeutisches praeparat und diagnoseverfahren | |
| EP0192098B1 (de) | Verwendung des 2-Amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepins zur Herstellung eines zur Behandlung der Parkinsonschen Erkrankung bzw. des Parkinsonismus geeigneten Arzneimittels | |
| DE2636328A1 (de) | Arzneimittel | |
| DE2855306A1 (de) | Mittel zur senkung der herzfrequenz | |
| DE2362783C2 (de) | Pharmazeutisches Kombinationspräparat zur Behandlung von Rhinitis | |
| DE1617822A1 (de) | Neues Kombinationspraeparat | |
| DE69001540T2 (de) | Arzneimittel zur rektalen verabreichung von calcitonin. | |
| DE2830610A1 (de) | Pharmazeutische zusammensetzung fuer die hemmung der prolactinsekretion |